MINI REVIEW article

Front. Mol. Biosci., 30 April 2020

Sec. Protein Folding, Misfolding and Degradation

Volume 7 - 2020 | https://doi.org/10.3389/fmolb.2020.00073

Heat Shock Protein 60 in Cardiovascular Physiology and Diseases

  • 1. State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China

  • 2. Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, United States

  • 3. Department of Cardiovascular Surgery, Peking University Shenzhen Hospital, Shenzhen, China

Abstract

Heat shock protein 60 (HSP60) is a highly conserved protein abundantly expressed in both prokaryotic and eukaryotic cells. In mammals, HSP60 has been primarily considered to reside in the mitochondria, where HSP60 and HSP10 form a complex and facilitate mitochondrial protein folding. However, HSP60 is also observed in the cytoplasm, the plasma membrane, and the extracellular space. HSP60 regulates a broad spectrum of cellular events including protein trafficking, peptide hormone signaling, cell survival, cell proliferation, inflammation, and immunization. In the cardiovascular system, growing evidence indicates that HSP60 could not only play an important role under physiological conditions, but also regulate the initiation and progression of heart failure and atherosclerosis. In this review, we focus on recent progress in understanding the function of HSP60 in cardiomyocytes, endothelial cells, and vascular smooth muscle cells (VSMCs), respectively, and discuss the related signaling pathways that have been found in these cells, so as to illustrate the role of HSP60 in the development of cardiovascular disease.

Introduction

The human heat shock protein 60 (HSP60), which is also known as 60 kDa chaperonin, belongs to a family of the most ancient and conserved proteins in both prokaryotic and eukaryotic cells. They have a high homology between species and are ubiquitously expressed in most cells. HSP60 was initially found as a mitochondrial protein that plays a critical role in regulating mitochondrial protein homeostasis (; ). It has been shown that human HSP60 and HSP10 form a symmetrical football complex (), whereas the bacteria homolog of HSP60, GroEL, is organized in two rings, producing a barrel-like structure (; ). A survey of interactors of the human HSP60 suggested that most HSP60-interacting proteins are localized to the mitochondrial matrix space and involved in various mitochondrial functions and metabolic pathways (). Interestingly, accumulating studies have demonstrated that HSP60 is also localized in extramitochondrial compartments including the cytosol, plasma membrane, and extracellular space, as well as in blood circulation (). Depending on protein localization, HSP60 not only regulates the mitochondrial chaperoning activity, but also plays a functional role in multiple cellular processes including cell proliferation, apoptosis, migration, and immune responses ().

The cardiovascular system is comprised of the heart and the network of arteries, veins, and capillaries that transport blood throughout the body. In humans, cardiovascular disease is a leading cause of mortality throughout the world (). It has been shown that many risk factors for cardiovascular disease, including smoking, lipopolysaccharide, chlamydia pneumoniae, shear stress, and ischemia, can promote the expression of HSP60 (). In the cardiovascular system, HSP60 has been supposed to play a regulatory role in cardiomyocytes, endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and immune cells under both physiological and pathological conditions such as heart failure and atherosclerosis. The functions of HSP60 in immune cells and immune regulation have been well addressed and discussed elsewhere (; ; ; ). This review focuses on the functional roles that HSP60 performs in cardiomyocytes, ECs, and VSMCs, respectively, and the involvement of HSP60 in the pathogenesis of heart failure and atherosclerosis.

Cardiac HSP60 and Heart Failure

HSP60 is highly expressed in cardiac tissues, and has been found in different subcellular locations inside cardiomyocytes, including on the membrane and in the mitochondria, cytoplasm, and extracellular space (; ). A large number of studies using in vitro cell culture models and in vivo animal models have revealed that HSP60 plays an important role in regulating cardiac physiology and pathophysiology. Here we describe several major roles of HSP60 in cardiomyocytes and the involvement of HSP60 in the progression of heart failure (Figure 1).

FIGURE 1

Intracellular HSP60 May Play Protective Roles in Cardiac Cells

In cardiac cells, HSP60 is mainly located inside the mitochondria, while a small portion of HSP60 (approximately 20–40%) can be observed in the cytoplasm (). In cultured neonatal rat cardiomyocytes, overexpression of HSP60 alone or together with its co-chaperone HSP10 protected myocytes against apoptosis induced by simulated ischemia and reoxygenation (; ). The protective function of overexpressed HSP60 and HSP10 is associated with reduced mitochondrial Cytochrome c release and suppressed Caspase-3 activity, as well as an increase of ATP recovery and elevated activities of mitochondrial complexes III and IV. These results suggest that mitochondrial chaperonin HSP60 plays a critical role in regulating mitochondrial integrity and capacity for ATP production, which are essential for determining the survival of cardiomyocytes undergoing ischemia and reperfusion injury.

Human mitochondrial HSP60 and its cochaperonin HSP10 form a symmetrical football complex (), which facilitates the folding of mitochondrial proteins and therefore confers their stability. This consequently prevents mitochondrial protein degradation and the induction of mitochondrial unfolded protein responses. Furthermore, HSP60 may protect mitochondrial proteins from aggregation, especially under stressful conditions. Myrtucommulone, a natural product that can inhibit the refolding activity of the HSP60/HSP10 complex, prevents the reactivation of denatured malate dehydrogenase in a protein refolding assay. Under heat shock, the interference of myrtucommulone with HSP60 is accompanied by aggregation of the Lon protease-like protein (LONP) and the leucine-rich PPR motif-containing protein (LRP130) (; ). In future studies, it will be very interesting to examine whether HSP60 deletion in cardiac cells could also result in the aggregation of certain mitochondrial proteins under stress.

HSP60 is also observed in the cytosol, where it may exist in monomeric or heptametric forms (; ). HSP60 is synthesized in the cytosol with a mitochondrial transport signal (). After translocation to the mitochondria, the mitochondrial transport signal is then cleaved and a certain amount of HSP60 protein may return to the cytosol. On the other hand, HSP60 with the mitochondrial target peptide may also be observed in the cytosol as the newly synthesized protein and accumulation of such proteins could be found in certain circumstance without apparent mitochondrial release (). However, the mechanism underlying the distribution of HSP60 between the mitochondria and the cytosol remains unclear. HSP60 in the cytosol has also been considered to play an antiapoptotic role in cardiac cells. Immuno-electron microscopy has demonstrated that HSP60 is co-localized with Bax in the cytosol of normal rat hearts (). The decrease of cytosolic HSP60 induced by an antisense phosphorothioate oligonucleotide facilitates the translocation of Bax to the mitochondria and induces apoptosis, evidenced by the release of mitochondrial Cytochrome c, activation of Caspase 3, and induction of DNA fragmentation (). Moreover, the hypoxia can trigger the disassociation of the HSP60-Bax complex, accompanied with the translocation of Bax to the mitochondria and cytosolic HSP60 to the plasma membrane, which may be sufficient to induce cell apoptosis in adult rat cardiomyocytes (; ).

HSP60 Is Essential for Maintaining Mitochondrial Function and Cardiac Physiology

The importance of HSP60 has been characterized in Escherichia coli and yeast, in which the deficiency of HSP60 leads to a lethal phenotype (; ). HSP60 is also essential for survival of Drosophila and mice (; ). Inactivation of the Hspd1 gene in mice results in early embryonic lethality while Hspd1 haploinsufficiency can also cause a late onset and slowly progressive deficit in motor functions (; ). Moreover, it has been shown that missense mutations in human HSPD1 gene are associated with two extremely rare monogenic disorders-hereditary spastic paraplegia and a recessively inherited white matter disorder (; ). Recently, we generated a mouse model with inducible cardiac-specific HSP60 deletion and investigated the role of HSP60 in regulating mitochondrial function and cardiac physiology (). We found that deletion of HSP60 in adult cardiomyocytes dramatically altered the activities of mitochondrial complexes, reduced mitochondrial membrane potential, increased ROS production, and eventually resulted in dilated cardiomyopathy, heart failure, and death of mice. Proteomic analysis in purified HSP60-deficient mitochondria suggested that about 20% of mitochondrial-localized proteins are HSP60-dependent, meaning they rely on HSP60 to mediate correct protein folding in the mitochondria. A survey of HSP60-interacting proteins was recently performed in HEK293 cells using co-immunoprecipitation and mass spectrometry and identified more than 300 proteins (), 46 of which including ALDH2, CPT2, IDH3A, and SUCLG2 were downregulated in mitochondria of HSP60-deficient cardiomyocytes (). Furthermore, an assessment of the mitochondrial protein import and stability found that deletion of HSP60 has no effect on mitochondrial protein import. However, HSP60 deletion impels HSP60-dependent mitochondrial proteins to undergo degradation after import, which suggests that the protein exhibits low stability in HSP60-deficient mitochondria. Moreover, deletion of HSP60 activates the mitochondrial unfolded protein response () and is also accompanied with increased cell apoptosis (). All these results together demonstrate that HSP60 is required for maintaining normal mitochondrial function and cardiac physiology.

Extracellular HSP60 May Have an Injurious Effect on Cardiomyocytes

It is now clear that HSP60 also exists in the plasma, as well as in the extracellular space of cardiomyocytes (; ; ; ; ; ; ; ), even though the exact mechanism underlying how HSP60 is secreted from cardiomyocytes is still under debate. First, HSP60 can be passively released as the intact or fragmented protein from damaged or dead cells, respectively (). Secondly, HSP60 in certain non-cardiomyocytes can be secreted through the conventional endoplasmic reticulum–Golgi secretory pathway (; ). However, a nonconventional secretion mechanism, the lipid raft-exosome pathway, is a more widely accepted way by which HSP60 in cardiomyocytes is secreted (; ). HSP60 in the exosomes is found to bind with the exosome membrane, and is released via exosomes in both the basal state and subsequent mild stress (; ). HSP60 can be used as a marker to indicate the number of extracellular vesicles released from the heart (). Alternatively, another point of view suggests that HSP60 may be stabilized within the exosome under multiple certain physiological conditions and is not released to prevent its toxicity to cardiomyocytes ().

It is worthy to note that HSP60 in the plasma/serum reflects the total amount of the protein released by all types of organs and tissues, and extracellular HSP60 (exHSP60) in the heart tissue can be released by cardiomyocytes via exosomes as well as by necrosis or other routes, as mentioned above. In any case, exHSP60 is generally considered as an injurious signal in cardiomyocytes (; ), even though exHSP60 has also been shown to play a beneficial effect on certain non-cardiomyocytes like B cells (). exHSP60 may function as a ligand for the Toll-like receptors (TLRs) in many cell types including cardiomyocytes. TLR4 is the most highly expressed subtype of TLRs in cardiomyocytes (; ), and has been considered as the receptor of exHSP60 (; ; ). exHSP60 can induce the release of tumor necrosis factor a (TNFα) and Interleukin 6 from cardiomyocytes, which can be impeded by the inhibitors of P38 and NFκB (). Meanwhile, exHSP60 also increases the expression of TLR2 and TLR4 in cardiomyocytes, which can be abolished by the inhibitors of JNK and NFκB (). Activation of NFκB eventually leads to the release of Cytochrome C and AIF from the mitochondria, activation of Caspase-3/7, and cell apoptosis in cardiomyocytes treated with HSP60 (; ). Consistently, treatment with an anti-TLR4 blocking antibody or deletion of TLR4 is able to totally abolish the exHSP60-induced cell apoptosis in cardiomyocytes (; ). In addition, exHSP60 released from cardiomyocytes via exosomes or in other ways may also play a role in regulating cardiac fibroblast and endothelial cell functions, and thus affects the adaptive responses of hearts under stress ().

HSP60 May Act as a Biomarker of Heart Failure

Heart failure, a process of chronic inflammation and progressive injury of cardiac muscle, is one of the most common complications of cardiovascular disease (). Heart failure can result from many forms of heart disease, including dilated and ischemic cardiomyopathy. It has been shown that the expression of endogenous HSP60 is significantly elevated in the myocardium of patients with dilated and ischemic cardiomyopathy (; ). During the progression of heart failure, NFκB is chronically activated, resulting in increased binding to the two NFκB binding elements in the HSP60 gene. This may account for increased expression of HSP60 in cardiomyocytes (; ). In addition to the overall change of the HSP60 protein, HSP60 may redistribute between different subcellular locations in the cardiomyocyte under stress. As mentioned above, HSP60 in the cytosol can be translocated to the plasma membrane, which may cause the movement of Bax to the mitochondria as well as the activation of Caspases and apoptosis in the cardiomyocytes during heart failure (). This is consistent with a finding that HSP60 levels in the cytosol is reduced in dilated cardiomyopathy (DCM) hearts ().

More importantly, serum HSP60 (sHSP60) may act as a biomarker for heart failure. Detectable sHSP60 levels have been observed in both healthy control human patients (; ) and patients with cardiovascular diseases (; , ; ). Acute myocardial infarction is able to induce HSP60 release, as manifested by a rise of sHSP60 levels soon after the onset of acute myocardial infarction and a positive correlation of these levels. Acute myocardial infarction also leads to adverse cardiovascular events and increased levels of creatine phosphokinase and troponin (; ). In patients with advanced chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy, sHSP60 is correlated to the severity of the disease and is associated with a high risk of adverse cardiac events (). In patients with acute heart failure, increased sHSP60 is also correlated with a higher risk for subsequent death/readmission for acute heart failure (). Thus, sHSP60 levels could emerge as promising independent predictors of adverse cardiac events. Alternatively, exosomal HSP60 can serve as a biomarker for diagnostics, assessing prognosis, and monitoring disease progression ().

Vascular HSP60 and Atherosclerosis

Atherosclerosis progression is a complicated process that involves the participation of endothelial cells (ECs), VSMCs, macrophages, and other lymphocytes (; ; ). In atherosclerosis, the endothelial cell layer is disrupted by oxidized low-density lipoproteins (oxLDLs) (). Macrophage foam cell formation occurs, and smooth muscle cells undergo migration and proliferation (). These mechanisms contribute to atherosclerotic plaque formation. It has been generally supposed that HSP60 is atherogenic (). HSP60 can activate both the innate immune system via TLR4 and the adaptive immune system (). However, the role of HSP60 in ECs and VSMCs has only been investigated in a limited number of studies. Here we describe the current understanding of how HSP60 functions on ECs and VSMCs, respectively, and discuss how vascular HSP60 is involved in the development of atherosclerosis (Figure 2).

FIGURE 2

HSP60 May Regulate Cell Survival of ECs

Various atherogenic risk factors including physical insult (shear stress and heat), chemical stress (smoking, oxygen radicals, drugs, high sodium, and high glucose), infection (e.g., Chlamydia pneumoniae), and inflammation (LPS, inflammatory cytokines, and oxLDLs) possess the ability to regulate the expression or localization of HSP60 in ECs (; ; ; , ; , ; ; ; ). Shear stress plays a major role in the generation, progression, and destabilization of atherosclerotic plaques (). Shear stress is able to induce HSP60 expression in ECs in vitro and in vivo (). ECs in atherosclerotic lesions of rabbits and humans also exhibit higher HSP60 levels than those in other regions of normal arterial intima (; ). Cigarette smoking is another significant risk factor for atherosclerosis (). It has been shown that prolonged exposure to cigarette smoke alters mitochondrial structures. As a result, HSP60 is released from the mitochondria, transported to the cell surface, and then dispensed into the cell culture supernatant in ECs. Thus, cigarette smoke exposure likely accounts for the increased levels of HSP60 found in the serum of healthy young individuals exposed to second hand smoke (; ). exHSP60 has been shown to induce TNFα in human umbilical vein ECs (). However, there is one exceptional condition in which exHSP60 is beneficial to ECs. exHSP60 may bind to membrane ATP synthase and serve a protective role against EC acidification and cell apoptosis in the presence of anti-ATP synthase antibodies (; ). On the other hand, downregulation of mitochondrial HSP60 in ECs is associated with accelerated apoptosis (), whereas overexpression of HSP60 in ECs may exert a protective role in digoxin-induced apoptosis (). A recent study using Tie2-Cre to delete HSP60 in both hematopoietic cells and ECs suggests that HSP60 may be required for embryonic erythropoiesis and vascular development (). However, it remains to be investigated in more detail whether and how HSP60 regulates EC physiology in vivo.

HSP60 May Regulate Proliferation, Survival, and Migration of VSMCs

It has been shown that the overexpression of the HSP60 with or without mitochondrial targeting peptide can induce an increase in VSMC proliferation (; ). exHSP60 may also play a very important role in regulating cell proliferation of VSMCs. Recombinant human HSP60 promotes cell proliferation in venous VSMCs, which can be inhibited by the application of TLR2 and TLR4 antibodies (). Interestingly, exHSP60 can also promote cell migration of VSMCs. VSMCs exposed to HSP60 exhibit increased cell migration, which is accompanied with increased expression of TLR4 and ERK activity. Knockdown of TLR4 or the use of ERK inhibitors can significantly reduce HSP60-induced VSMC migration (). On the other hand, cytosolic HSP60 plays an anti-apoptotic role in VSMCs. Deletion of cytosolic HSP60 in VSMCs is found to reduce the IκB kinase activation, repress the induction of NFκB-dependent survival genes, enhance apoptotic death in response to TNFα, and markedly inhibit the neointimal thickening in the balloon-injured arterial vessels ().

HSP60 Is Atherogenic

Under stressful states, HSP60 is translocated to the cytosol and appears on the plasma membrane and in the extracellular space. HSP60 can also be directly released from damaged and dying cells (; ). Higher expression of HSP60 can be found in ECs in atherosclerotic lesions of rabbits and humans compared with those in other parts of normal arterial intima (; ). Consistently, elevated levels of soluble or circulating HSP60 have been shown to correlate with an increased risk of atherosclerosis (; ; ; ). HSP60 on the membrane and in the extracellular space has been widely considered to act as a danger signal to the atherosclerosis in several aspects. First, HSP60 has a high degree of homology in both protein and DNA levels between different bacterial species, and from prokaryotic to eukaryotic cells (; ). All humans develop cellular and humoral immunity against bacterial HSP60 either by infection or vaccination. This protective defense may increase the risk of cross-reactivity with autologous HSP60, which causes the adhesion of HSP60-reactive T cells to the endothelial cells and the initiation of the earliest inflammatory responses of atherosclerosis. In addition, antibodies against HSP60 are able to accelerate and perpetuate the disease (; ; ; ). If the reversible early inflammatory stage of atherosclerosis is not interfered or risk factors remain present, irreversible late stages with atherosclerotic plaques will develop and lead to clinical consequences. Second, exHSP60 can react to TLR4 expressed in endothelial cells, smooth muscle cells, and macrophages (), as well as activate NFκB-dependent signaling pathways. It can also promote the production of various proteolytic enzymes and cytokine such as TNF, IL10, adhesion molecules, and growth factors (). Third, exHSP60 may induce the proliferation and migration of VSMCs (; ; ; ), which may further accelerate atherosclerosis.

Conclusion

It is now clear that HSP60 plays multiple regulatory roles in cardiovascular physiology. Mitochondrial HSP60 together with its chaperonin HSP10 regulates mitochondrial protein folding. Deletion of HSP60 results in mitochondrial dysfunction, chamber dilation, and heart failure. HSP60 undergoes subcellular translocation and secretion in response to stress and cell / tissue injury, and is considered as a pathogenic signal in heart failure, atherosclerosis, and other cardiovascular diseases. exHSP60 may induce cell apoptosis in cardiomyocytes and thus exacerbates the disease state of heart failure. exHSP60 may also participate in the initial step of atherosclerosis by inducing multiple inflammatory responses, and accelerates the progression of atherosclerosis by promoting VSMC cell proliferation and migration. All of these results have provided us with a better understanding of HSP60 functions in the cardiovascular system and may contribute to the future development of novel therapies targeting HSP60 for the treatment of cardiovascular disease.

Statements

Author contributions

YD, HT, KM, XF, ZH, and KO wrote the manuscript.

Funding

This work was supported by the Shenzhen Basic Research Foundation (JCYJ20160428154108239, KQJSCX20170330155020 267, JCYJ20170818090044949), the Guangdong Province Basic Research Foundation (2018A030310012), the National Key Basic Research Program of China (2013CB531200), and the National Science Foundation of China (81700289, 31800767, 81970421).

Acknowledgments

We would like to thank Dr. Ju Chen at University of California, San Diego for critical reading of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Summary

Keywords

heat shock protein, HSP60, heart failure, atherosclerosis, cardiomyocyte

Citation

Duan Y, Tang H, Mitchell-silbaugh K, Fang X, Han Z and Ouyang K (2020) Heat Shock Protein 60 in Cardiovascular Physiology and Diseases. Front. Mol. Biosci. 7:73. doi: 10.3389/fmolb.2020.00073

Received

10 January 2020

Accepted

31 March 2020

Published

30 April 2020

Volume

7 - 2020

Edited by

Antonella Marino Gammazza, University of Palermo, Italy

Reviewed by

Paula Fernandez-Guerra, Aarhus University Hospital, Denmark; Magdalena Gorska Ponikowska, Medical University of Gdańsk, Poland

Updates

Copyright

*Correspondence: Zhen Han, Kunfu Ouyang,

†These authors have contributed equally to this work

This article was submitted to Protein Folding, Misfolding and Degradation, a section of the journal Frontiers in Molecular Biosciences

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics